Counting my change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What know one understands is you can't take internet orders when you have large demand that needs to filled first,then you can focus on the internet orders.Take care of the big orders first!
You are 100% right!!!!!!!!!!
If you really believe what you are saying then why would you still be vested in EVRN?
Everything I ever said has been factual. The main concern is to fill existing demand then move into internet orders,Costco,and Walmart.Everything step by step.Robert is the direct connection to EVRN and so his money.Most all PRs are from him.
Hi Tim,
I will get these questions answered.if there is any more questions people have please let me know soon,as I will call him again tomorrow.
As far as the "Seller" he had 70 million free shares and Robert believes that he is done selling,but he will find out and let me know for sure.
The website is not currently a priority. They have built up demand already waiting for there product which is bigger than the website potential orders. I told him about the site and they are making some changes.
I have been in constant communication with Robert.I seem to have a good relationship with him. We should see another PR most likely sometime after the first. We will hear about the production schedule and the already built up high demand for the product.Every step has been calculated. Again he told me he rarely invests his own money.$200,000 of his own money as well as more personal money from the CEO.That to me spells confidence.He has told me more than once financing is not a problem.I also like the idea that their PRs are not fluff but good hard news.As far as the "Seller" he had 70 million free shares and he believes that he is done selling,but he will find out and let me know for sure.
Well there is the facts...Happy Holidays and lets all make some money!
There is no symbol change. I already checked with e-trade
Hemispherx Biopharma, Inc. (HEB) is “One to Watch”
By Jonathan
04 December 2009 @ 05:35 am ET
Hemispherx Biopharma, Inc. (AMEX: HEB) is a biopharmaceutical company focused on the manufacture and clinical development of new drug entities designed to treat viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens®.
The company’s platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx’s core intellectual property estate consists of more than 100 patents covering various forms of double stranded (ds) RNA and their fields of therapeutic application, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products.
Hemispherx is currently engaged in broad-based ongoing experimental studies assessing the efficacy of their products Ampligen®, Alferon N Injection® and Alferon LDO® against influenza viruses as an adjuvant single agent antiviral with the Defence R&D Canada, the National Institute of Infectious Diseases in Tokyo, the Princess Margaret Hospital in Hong Kong and various research affiliates of the National Institutes of Health in the United States.
In the company’s most recently reported quarter, a 29% reduction in net loss and a nearly 10 fold increase in cash/cash equivalents was recorded. The net loss reduction was a result of lower R&D and G&A expenses, while the substantial increase of cash/cash equivalents reflects the net proceeds of two equity placements as well as an equity financing agreement. With $62 million in total current assets and only $1.4 million in total current liabilities, the company maintains a very strong balance sheet
From Ihubber Probart
XCHO Xenacare(XCHO)Valuation Report,shows potential for a 50 baggerThoughts?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44551225
There is an apparent lucrative investment in a company called Xenacare (XCHO) that is the exclusive distributor of Cobroxin (www.Cobroxin.com). Cobroxin is the first non-prescription pain med that can treat moderate pain (normally treated by Vicodin, Morphine or other opiates). The reason it is non-prescription is that there is no "high" thus is non-additive and the dose is very small. The product was developed by NutraPharma (NPHC) which has already made a run in August-September of over 20 times based on the Cobroxin news.
I have pulled info from several sources into this report. In a nutshell they have a new pain killer Cobroxin that has been placed in stores like Winn-Dixie and on websites like Amazon. It appears to be a blockbuster, yet XCHO only has about a $6 million market cap. NPHC has released sales projections of 1,000,000 units a month. So far they say introductory sales are exceeding expectations. They have said by the 2Q of 2010 it will be on the shelf in 40% of the drug stores in America. XCHO has exclusive marketing rights to Cobroxin. Check it out, I think you will like what you see.
The CEO of NutraPharma Rik Deitsch http://people.forbes.com/profile/rik-j-deitsch/59117 has said in a webinar in September which is very informative on the technology the 1,000,000 units a month projection after it been fully rolled out. Here is that presentation: http://www.nutrapharma.com/investor_relations/presentations.php. Also he gave another presentation last week that should show up at that link soon.
BTW for full disclosure I have a position in both NPHC and XCHO which I have increased significantly in the last month as the effectiveness of the product has been proven from multiple sources including a MD. The most active stock
board on XCHO is Yahoo, I would suggest viewing it for additional info.
Lets look at valuations. Currently NPHC has 110 million market cap and got to a $220 million market cap http://finance.yahoo.com/q/ks?s=NPHC.OB. They have 269 million shares out. Xenacare (XCHO) in comparison has a $6 million market cap and only 66 million shares out of which only 47 million is float http://finance.yahoo.com/q/ks?s=xcho.ob. NPHC does have the advantage of additional drugs in the pipeline, but the gross sales of Cobroxin will first go to XCHO, then NPHC will get its cut. Since Rik uses the figure of 1 million bottles a month what will that translate into? XCHO is selling it briskly now online on its own site (www.Cobroxin.com) for $19. They wholesale for $10 from reports we have from a MD. Sites like Amazon.com and Overstock.com have had trouble keeping it stocked, it is selling apparently above their expectations. So to guess at Xenacare's (XCHO) long term average sales price I will use $11 a bottle. That is $132,000,000 in sales per year for a company with a market cap today of $6,000,000. Hence the opportunity. A rapidly growing company often gets a 5x or 8x Sales valuation. Lets say XCHO only gets a 3x Sales and the stock is diluted 25% as the PPS goes up. That would push XCHO from the current .09 to $4.95 per share. That would be a 55 bagger or 55 times current price. Lets say the CEO of NPHC is way off on his projections, and it is only 250,000 bottles a month. That would still be at a measly 3x Sales $1.24 a share or a 14 bagger.
As the name implies the product is highly dilute peptides derived from cobra venom. The pain killing ability of this has been known for centuries and the US Army used it along side morphine in WW2. It was then unstandardized and the mechanism was unknown. Those issues have been solved. It works especially good on arthritis pain BTW. Cobroxin won Product of the Year when it was announced http://www.news-medical.net/news/20090831/Nutra-Pharmae28099s-Cobroxin-pain-reliever-is-Best-New-Product-at-the-ECRM-Conference.aspx. Here are some testimonials http://www.cobroxin.com/testimonials.php Also here are the Amazon.com product reviews: http://www.amazon.com/CloseoutZone-Chronic-Pain-Reliever/dp/B002VFYHGA
Here are the notes from the 12-10-09 Webinar by Rik the CEO of NPHC which has not yet been archived. He said that up front it was not for investors but for users, but we got tons of news anyway.
1. Nyloxin OTC is foreign name of Cobroxin.
2. He said he was happy with Xenacare and how Cobroxin is being rolled out by Xenacare (XCHO).
3. He said by 2Q all major drug chains will have it and 40% of all drug stores in USA. This is on the shelf and it will result in 2Q sales explosion.
4. He gave us 5 retail chain names that have it on the shelf with close to 2,000 stores combined. The list is:
Winn Dixie 600 stores
Myers 173
Dwanye Reed 250 (NY)
Hannaford 250
Stop &Shop 375
BTW the CDMA already has ordered it and they have 6,000 outlets in 32 states: http://www.pr.com/press-release/191604
5. They do plan a pet version.
6. It is less expensive per month than Advil.
7. It is 5 micrograms per spray.
8. Overdose almost impossible, researcher drank 36 bottles and got double vision and headache only.
9. TV ads will start running in January. In magazines now.
Prior info we have is customer reviews at Amazon:
http://www.amazon.com/CloseoutZone-Chronic-Pain-Reliever/dp/B002VFYHGA
5 Reviews
5 star: (5)
4 star: (0)
3 star: (0)
2 star: (0)
1 star: (0)
Average Customer Review
5.0 out of 5 stars (5 customer reviews)
Most Helpful Customer Reviews
4 of 4 people found the following review helpful:
5.0 out of 5 stars Great new pain reliever, November 3, 2009
By Ruben Rivera (Minneapolis, MN USA) - See all my reviews
(REAL NAME)
I ordered this product several days ago and applied it according to the directions on joints that have been giving me chronic pain for years. The instructions say it takes 3 to 4 applications per day for about 4 days for it to become effective (then you can reduce the number of applications per day), but I was getting relief within a couple of days. Cobroxin is working great with none of the side effects the FDA says accompany many of the common pain relievers out there. This is great stuff.
4 of 4 people found the following review helpful:
5.0 out of 5 stars This product really works!, November 3, 2009
By A. Nel - See all my reviews
(REAL NAME)
I have purchased and used both the gel and the spray. I was a bit skeptic at first. It has been VERY effective on both a chronic elbow pain and the spray has worked wonders for my migraine problem.
There are no side effects associated with this product that one would get using over the counter drugs and prescription medications. It relieved me of serious pain within thirty minutes.
Thanks Cobroxin, awesome product! Comment Comment | Permalink | Was this review helpful to you? Yes No (Report this)
2 of 2 people found the following review helpful:
5.0 out of 5 stars Cobroxin Works!!!!, November 3, 2009
By AlexD (Florida) - See all my reviews
Unbelievable. There is no other word to describe this product. I bought it for my girlfriend who has had pain in her hip for years. On only the second day after the first application, she walked to the grocery store not once, but twice, and without pain. Previously, she would get sore on the way there and suffer all the way back. This is one of those things that seems too good to be true, but is just THAT good. I'm so impressed, I already ordered more for two of my friends who suffer daily. I almost wish I had an ache of my own to try it out on!! Comment Comment | Permalink | Was this review helpful to you? Yes No (Report this)
Conclusion: The Risk/Reward Raton on XCHO is extraordinary and a 10-20-50 bagger is feasible. Please do your own due diligence and report what you find.
Cheers
Health Sciences Enters Into LOI With The Healing Center of Montana to Acquire Two Medical Marijuana Licenses
* Press Release
* Source: Health Sciences Group, Inc
* On 12:53 pm EST, Tuesday December 15, 2009
INDIAN HARBOR BEACH, FL--(Marketwire - 12/15/09) - Health Sciences Group, Inc. (Pinksheets:HESG - News) would like to announce that it has entered into a letter of intent with The Healing Center of Montana to purchase two operating licenses for medical marijuana collectives in Park County, Montana and Lake County, Montana. This transaction is contingent with standard due diligence and anticipated to finalize before the end of the year.
The Healing Center of Montana, owned and operated by Mike Smith, is the largest medical marijuana operation in the State of Montana and also has a presence in Colorado. Mike Smith has been in the Montana medical marijuana business since the state went legal.
"We anticipate this transaction to move very quickly, by the end of the month if not sooner. Contracts and agreements are going back and forth between the companies right now," stated Thomas Gaffney, CEO of Health Sciences Group, Inc.
Gaffney continues, "Health Sciences Group intends on being the first public medical marijuana company to derive actual revenues from medical marijuana operations. Although The Healing Center is non-profit, these two new locations would be for profit under a management agreement."
Montana, unlike California, allows collectives to be for profit.
ABOUT HEALTH SCIENCES GROUP, INC.
Health Sciences Group, Inc. is a provider of health and wellness services to consumers, physicians and other healthcare professionals through its website, www.igohealthy.org, and health focused publications. The Health Sciences network consists of its public website, www.igohealthy.org, and iGoHealthy Magazine. The Company operates in three segments: Online Services, Publishing and Other Services. The Company is recently exploring options of corporate growth within the Legal Medical Marijuana Industry.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Health Sciences Group, Inc. to be materially different from the statements made herein. Investors are highly advised to seek professional advice and conduct a complete due diligence regarding this, or any other company being considered for investment purposes. Investing in securities, particularly in issues priced at less than $1 per share, involves substantial risk and may result in a partial or complete loss of investment capital. Health Sciences Group, Inc., its subsidiaries, officers and employees cannot guarantee the completeness or accuracy of the information contained in company press releases or other company communications. Press releases and communications issued by the company should not be interpreted as an offer to sell or a solicitation to buy company stock.
?
CONTACT:
Health Sciences Group, Inc.
Investor Relations
Frank Godleski
IR Representative
Email Contact: info@igohealth.org
Investors are highly advised to seek professional advice and conduct a complete due diligence regarding this, or any other company being considered for investment purposes. Investing in securities, particularly in issues priced at less than $1 per share, involves substantial risk and may result in a partial or complete loss of investment capital. Health Sciences Group, Inc., its subsidiaries, officers and employees cannot guarantee the completeness or accuracy of the information contained in company press releases or other company communications. Press releases and communications issued by the company should not be interpreted as an offer to sell or a solicitation to buy company stock.
Contact:
CONTACT:
Health Sciences Group, Inc.
Investor Relations
Frank Godleski
IR Representative
Email Contact: Email Contact
Just talked to Robert a second ago He is very excited about this product and getting it into production. He made it clear he rarely invests his own money in his ventures,but he feels extremely confident in this product line.He agreed he would not be putting his $200,000 into a lottery pick.He mentioned that they do have product commitments for January,but the production schedule has not been set.
PS. I asked him about the seller.He stated the seller had 70 million free shares and he believes that he should be almost done if totally done by now,he isn't sure though. He told me he will find out for me.
We are looking Fantastic!!!!!!!
As always do your own DD
Just for the Record...EVRN Great News!
I talked to Robert just now 12/10.PR in 24 hours!!Great news financing is moving forward and a non issue for initial production.A matter of fact both Robert and Paul Wilkinson’s have personal money in the game and just added more.Demand for the products is extremely high(we will hear more of this in the PR).Everything is moving as planned.He apologized for the silence,but he has been traveling and is conservative when giving out info until everything is in place.Things are on the move.....
I love you too.
EVRN NEWS OUT!!!
I don't know why he told me 24hrs last week ,but I called Robert again and he said he was finishing it up now.
Reconfirmed Information coming to us soon.
I called Etrade again and they confirmed no symbol change at this time.
I just called Etrade,there is no symbol or status change OTC means not traded on an exchange.
My Etrade shows EVRN: OTC is that what yours shows? weird
When you talk to Robert and he gives you information,I would hope that is factual. This was never my opinion,it was stated fact by Robert. Why do people criticize instead of picking up the phone and call him themselves? I am here to make money just like you.
Robert admitted that his silence was a mistake.I agreed
Those were Roberts exact words.Why the element of surprise? Prs are what keep us informed.I am taking my time to talk to him to provide all of us information. This should be appreciated.Remember anyone can call him directly for updates.
Call him yourself. If you look back at my previous posts of discussions with Robert they have been spot on.I am trying to give people like you good information.
Always do your own DD.
No, but what he did say is the cost of raw materials has gone up and they needed to adjust for that which is not a problem.
Cord Blood America Announces Marketing Alliance Between CorCell and Blue Cross Blue Shield 10-Dec-09 05:34 pm
LOS ANGELES and PHILADELPHIA, Dec. 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that CorCell, Philadelphia, Pa., whose operating entity and assets were recently purchased by the Company, has signed a marketing alliance with Mountain State Blue Cross Blue Shield (MSBCBS), the largest health insurer in West Virginia.
"This alliance will bring the knowledge and awareness to MSBCBS members, providers and corporate, union ...
EVRN Great News!
I talked to Robert just now 12/10.PR in 24 hours!!Great news financing is moving forward and a non issue for initial production.A matter of fact both Robert and Paul Wilkinson’s have personal money in the game and just added more.Demand for the products is extremely high(we will hear more of this in the PR).Everything is moving as planned.He apologized for the silence,but he has been traveling and is conservative when giving out info until everything is in place.Things are on the move.....
BIEL-My phone call with Andrew Whelan CEO (12/09/2009)From the yhb
Just thought I will put this out here if it helps anyone. BIEL is going through a rough patch for no reason. Lot of us (including me) are losing a lot of money as of now. We all invested in the company because we truly and honestly believe in the company and its products. I am publishing this for only those who care. Bashers and doubters can go to hell. I am not a paid PR person, so I couldn’t care less about what you have to say. I took the initiative to call Andrew when I was in doubt and I am just sharing this with you all. Also, I added 166k more shares at .05.
I sent Andrew an email first with some questions in it which I had collected from lot of us on Yahoo boards and chatroll. He replied to my email with a canned reply first, but when I asked him again to reply to my questions, he sent me his phone# and asked me to call him. I kept trying to call him for 15 minutes but the phone was engaged. Finally, I got through but the receptionist picked it up and told me the Mr. Whelan was on another call and it maybe a while before he is free. I left my cell# with the receptionist (not expecting her to deliver my message at all). But I was pleasantly surprised when Mr. Whelan called me himself on my cellphone. I had a long conversation with him but I am just putting here questions that I specifically had him answer for all of us :
* Do we still have to wait into next year, or is reclassification of PEMF expected in December?
A: I have worked with this company for 10 years now. We had tried to re-classify PEFM technology under class-2, two years back, but FDA just turned a blind eye to our application and never even acknowledged it. This time we have lot of positive response from FDA and they are working with us and asking for documentation and supporting evidence as they review our application. This is very positive news and we are working very hard to make sure that FDA gets everything they ask for. As far as the dates are concerned, it won’t be fair for me or anyone else to announce a date. We all know how these govt agencies work. FDA takes 1 week to type up a letter. And at this time of the year, people may be going on vacation. December is always a slow month.
We already have class-3 approval for our products from FDA. Here is the debate about moving it to class-2. For class-2 these are the two important questions that are asked :
* 1. Can the patient diagnose himself or does a Doctor need to diagnose the disease for him?
No one needs a doctor to tell them that they have back pain or muscle pain. You can pretty much figure it out yourself where you have the pain. This is not lung cancer or something like that where you need to go to a doctor so that he can run a battery of tests to give you the verdict.
* 2. Can the patient consume a medicine on his own or does he need medical supervision to control the amount ingested into the body?
Actipatch and Allay are not going to be ingested into your bloodstream. These are simple devices with an on/off switch. When you don’t need the therapy turn it off.
As you can see the arguments are very simple and the answers more than obvious.
* Analyst Carrie Snyder predicted 0,30 to 0,50 by end of the year. Right now things seem to be a disaster. Would you care to comment?
A: Carrie Snyder’s valuation still holds absolutely correct. This stock is easily valued at .50c on FDA approval.
* SmallCap Network is constantly damaging your stock by giving very negative technical comments about it,and everytime they do it, the stock drops violently.To add to this TheStreet.com is further fueling the fire by release negative articles every now and then. Are you planning to do anything about this?
A: Frankly speaking, I have no control and don’t even care about what X person on an XYZ.com thinks about BIEL. They have their right to an opinion and I cannot control that. All I can control is that I will take this company where I want it to be. I am going to take care of our shareholders and we are working hard to do everything to get re-classification and to get international sales going in a big way.
* How quickly are you going to resolve the Scottrade and Ameritrade issues? This is really hurting all of us by creating an imbalance between buyers and sellers?
A: Unfortunately, we have no control over Scottrade and Ameritrade. They are complaining about a delay from DTCC (Distribution and clearing house) for our shares and that is why they have put restrictions on several other penny stocks too to protect their own interests. Being a pinksheet stock comes with all these problems. All that we have control over is that we are making lot of efforts to move to another exchange. The soon to be announced audit results will be a part of this equation to help us move to another stock exchange. This will help remove the pinksheet lable of our company and will automatically fix all the problems with these brokers.
* The sudden drop in stock price definitely begs some explanation. Please comment.
A: I have been with this company for a long time. My focus in life is clear. I want to take this company somewhere and that will happen with FDA OTC clearances and when revenue starts pouring in after the DRTV ad campaign goes live. A few cents drop in the PPS doesn’t bother me at all. This is not a daytraders stock. This is a stock which you buy and hold. The pain market is a billion dollar market. Once our products start selling in all the countries, revenues will hit the roof. And in the first quarter next year, when we will have sales/revenue numbers to report, things will speak for themselves.
* There is lot of talk that a Reverse Split is impending. Please comment. Also, the company has diluted the shares to the max. When is this going to stop?
A: Most pinksheet and pennystocks go through reverse split. This becomes essential at some point. But I can assure you that there is no talks of Reverse Split right now. We will get the company in a good shape with real revenue/sales numbers before there is even a talk about reverse split. As far as dilution is concerned. Yes, we have tapped into the stocks whenever we need funding. But there is a reason why we are going big time into sales promotion now. Sales means revenues. And that means no need for further dilution.
* If the company doesn’t get the re-classification, can it still go ahead and do the infomercials ?
A: If you notice we are starting the DRTV campaign in lot of countries. (He mentioned several countries. I don’t remember all. Germany, Turkey, Canada, South America were amongst them). We don’t have to wait on FDA for all these countries. We can sell our product without any problems. The most exciting thing that shareholders should look for is the DRTV ad campaigns. Once these start airing (starting Dec 10 I think – Jan 16th in all these countries), revenues will start pouring in.
* When is the Audit going to be completed? Is OTC BB on the cards?
A: The audit is almost complete. I will get the Audit results out in 1 or 2 weeks at the max. There was no problem with the Audit. It was very smooth. The audit was done 2006, 2007, 2008. These results should put us in good shape and help create transparency for shareholders.
* There are people claiming to have Insider info about the company. These people claim to know things about the company and PRs about to be released before the news even comes out. This is very scary for the rest of us honest shareholders. How is insider info leaking out ?
A: This is the first time anyone has brought this to my attention. We don’t reveal any strategies, decisions to any one. Because this is illegal. Obviously, I don’t want SEC knocking on my door. Please call me directly whenever you spot an incident of someone claiming to have insider info. Also, I heard some people claiming that the company is being bought out. These are very irresponsible statements. I will never put any information like that out there, unless I have a written and signed contract in front of me.
* Does Joe not work for the company anymore? His absence has become noticeably conspicuous now. Lot of people think that he has done more damage to the company than good, since he is busy promoting his other stocks all over the BIEL board.
A: Yes, Joe still works for the company. He is not an employee and is a contractor hired for PR purposes. His job is to get information out to the shareholders. And he does a great job with it.
(This is my own answer to this question. Frankly speaking, you will not find EVEN A SINGLE POST by Joe ever cross-promoting any other stock on the yahoo boards. I have gone through all his posts and I think this question was completely unfounded and unfair on Joe)
5855000 buy @.037
5855000 buy @.037
Key Alert on GCKO!!
Update on GeckoSystems For Thursday 12/10/09
Written by Peter DePalma
Thursday, 10 December 2009 05:49
The stock which we put on our watch list some days ago closed up in trading at the end of the day yesterday and is back on the radar screen for our subscribers.
We are concluding our special report nd will be breaking some major news about Gecko Systems International (GCKO.PK) some time during the trading day.
We are confirming one last, but very important detail about a second publicly traded NASDAQ company that is tied to the pending news story.
Geckosystems Intl Corp
Quotes delayed at least 20 mins.
As others have been speculating, the Georgia based company is expected to announce soon that it will be moving its CareBot eldercare/health care robot prototype from current in-home trails to production. The company aims to compete with it's much larger competitor iRobot (Nasdaq:IRBT) and their new health care robot division which have similar patented technologies designed to help the elderly.
Stay tuned for that news later today, perhaps even as late as this afternoon.
Update BIEL from Joe Noel 9-Dec-09 01:38 pm
Hello Everyone:
Back by Popular Demand - Here are the latest updates.
Reclassification Application - Personnel at the Company are in process of preparing the application requesting reclassification from Class III to Class II. The application will include several reports from scientists and physicians that will discuss the technical aspects of the product and arguing that the device is extremely safe and is incapable of causing harm. Additionally, the application will include many other supporting documents. We expect the application to be completed very shortly and to be filed with the FDA soon, likely over the next few days – and possibly even sooner. This is obviously an important application, so the Company is being very careful to make sure all of the proper documentation is included. Its worth noting this is a separate application from the others that have been filed. Because the FDA is actively reclassifying Class III devices cleared under 510K (such as BIEL’s), we expect a rapid review from FDA. In fact, we had been in discussions with the actual reviewer and they are presently awaiting our data.
International Developments – The Latin American launch is currently pending and we are optimistic about our prospects. We have contracted with one of the leading Latin American oriented advertising firms and the ads will be seen in most major Latin American countries. DRTV campaigns are also scheduled for Germany and Turkey. Canada is also in the schedule. These campaigns were designed by some of the best advertising firms in the business with extensive track records of success. We believe these international programs, along with other programs targeting Asian countries that are currently being designed, will yield substantial revenues in 2010.
The Audit – We met with the head auditor last night. We are happy to say that there are no outstanding issues raised - everything looks good based on what they are telling us. Very good news. The audit began at the end of October. Audits typically take approximately 60 days. The auditor’s review has been done and we are expecting their completed report in the very short term. I would like to emphasize here that we selected a solid medium-sized auditing firm in order to add credibility to the process. Accounting and auditing firms often give lower priority to smaller companies and sometimes these clients end up at the bottom of their auditing pile, thereby requiring a little more time to complete the process. We should have the final report any day according to the auditor. This should accelerate movement to the OTC - All excellent developments.
Movement to OTCBB - We are currently in process of executing a strategy to move off of the pink sheets and over to the over-the-counter (OTC) market. Andy and I will be meeting with the bankers in New York on Thursday and Friday regarding this process. We believe the completion of the audit should significantly facilitate the movement of the Company’s stock off the pink sheets, which in turn should result in the resolution of several issues with the electronic transfer of shares through brokerage house back offices.
Our Level of Confidence – It has not changed one bit. We think 2010 is going to be a fantastic year. Thanks for all your support. We believe everything is on track.
Joe Noel
GCKO Update 12/09/09
Written by Peter DePalma
Wednesday, 09 December 2009 05:21
Those of you watching GeckoSystems International Corporation (GCKO.PK) will be interested to know that M.E. Garza will be publishing his special report on the company this week.
Robot Safety Applauded During GeckoSystems' Elder Care Robot Trials
(published 12/09/09)
Robotic Stocks: iRobot Corp. (NASDAQ:IRBT) and Geckosystems International (GCKO.PK)
(published 12/08/09)
The company had some news this morning, but as hinted about in previous news releases, they are expected to announce more important developments sometime in the next few days.
Shares closed 13% higher on Wednesday in anticipation of that important news.
Yesterday, the company was listed alongside I-Robot (Nasdaq:IRBT) as one of the sector's hot stocks to watch. Since 1997, GeckoSystems has been developing a comprehensive, coherent, and sufficient suite of hardware and software inventions to enable a new type of home appliance (a personal robot) the CareBot(TM), to be created for the mass consumer marketplace.
MEDCLEAN ADVANTAGES from Analyst: Robert Goldman
• Management’s approach is to offer cost-effective solutions for preferable, on-site disposal to the Large (and also the Medium-Sized segment) Quantity Generators that are presently using off-site disposal today.
• This approach is unique as the field is less crowded than those utilizing the off-site approach.
• MedClean’s proprietary offering is a technology innovation and is patent pending.
• Management has an impressive track record of success, as evidenced by the success of eResearch Technology, which at one time rose from a sub-$50M market cap to $1.5 billion during their watch.
• Some of the competitors have had strong success, such as industry leader Stericycle (NASDAQ: SRCL), who, after recent M&A activity, is now forced to divest some RMW disposal assets, opening the door for MedClean.
• Other players, such as Sharps Compliance (NASDAQ: SMED), which has a 5-year CAGR of over 30%, are essentially one-trick ponies, focused on the disposal of sharps, almost exclusively, rather than the disposal of multiple RMW products.
• MedClean has recently raised $7.5 million, substantially adding to its cash position which will help grow its business in 2010.
• Despite its small size, MedClean generated a 22% operating margin for 3Q09, which bodes well for profitability in 2010 and beyond.
INVESTMENT RISKS
In our view, the greatest risk to these shares is an economic one, as evidenced by the slowdown during the recession. While there is demand for viable on-site RMW disposal systems, there could be delays in procurement by customers due to uncertainties surrounding the Obama Administration’s proposed health care plan and budget constraints. Other risks include competition from companies with similar and or differentiated technologies or approaches leading to fragmentation of the market in general. We believe that MedClean’s unique approach, IP, recent success, and management experience negates these risks somewhat, though swift, broad adoption may not occur pending greater market education. In our view, all of these risks are consistent with the companies of MedClean’s size. Thus, investors should use progress in distribution, sales and other news as a performance measure since these shares will be news-driven in the near term.
VALUATION AND CONCLUSION
Based on our analysis, we believe that MedClean is uniquely positioned to become a serious player in the RMW disposal market. The Company’s management team has done a remarkable job, growing revenue to $1.56M with operating profit of nearly $350,000 in 3Q09, versus a loss and revenue of only a few hundred thousand in 3Q08. With the right product for the right market, the Company should continue to enjoy success and grow at a rate faster than the industry average. Presently, the peer group of publicly traded companies, including SRCL and SMED, are trading around 4x trailing twelve months revenue and anywhere from 15 – 30x trailing twelve months EPS. MedClean currently trades around 7.0x twelve months trailing revenue.
Following a good 3Q09, we believe that MedClean could generate revenue in the $2.0M range in 4Q09, up from $1.56M in 3Q08. Also, our preliminary forecasts project that MedClean revenue could reach the $12-15M range next year, with net of $2.0 -$3.0m. Considering the high growth rate, and level of profitability, we believe that the shares could reach $0.14 in the near term, which reflects both a 30x on 2010E net, but also 8x our preliminary 2010 revenue forecast. Given that the stock is still currently under the radar of most investors following this space, we believe the shares are attractive at current levels. As investors become more familiar with the MCLN story, and management continues to execute, this news-driven stock could reach $0.40 in 1H10. Thus, we rate these shares Speculative Buy.
Cord Blood
America Announces Grand Opening of Lab, Corporate Offices on January 22, 2010
LAS VEGAS, Dec. 8 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today its Grand Opening for its Las Vegas corporate office and laboratory, to be held at Noon – 5 p.m. on Friday, January 22, 2010.
The event will include a ribbon-cutting ceremony at Noon and tours of the laboratory facilities throughout the afternoon. Please visit http://www.cordblood-america.com/grandopening to RSVP, sign up for tours and print a map and directions to the office. The facility is at 1857 Helm Drive, Las Vegas 89119, near the city's airport.
"We are looking forward to sharing this momentous day with our customers, shareholders
, friends and potential investors," said Matthew Schissler, Cord Blood America co-founder and CEO.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
http://finance.yahoo.com/news/Cord-Blood-America-Announces-prnews-123675958.html?x=0&.v=1
That is an estimate...no dates with the FDA are for sure.
GLTA
STRAYER DAVID R Adds more
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6642574